Purple Biotech narrows Q1 net loss as cancer pipeline progresses
Purple Biotech (NASDAQ:PPBT) reported its financial and operational results for the first quarter of 2026, highlighting clinical milestones within its immunotherapy pipeline and a stabilized bottom line supported by non-operating income.










